Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT) have earned an average rating of “Moderate Buy” from the nine analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $14.3333.

Several research firms have recently issued reports on ALT. Leerink Partners assumed coverage on shares of Altimmune in a research note on Monday, June 22nd. They set an “outperform” rating and a $10.00 target price on the stock. HC Wainwright restated a “buy” rating on shares of Altimmune in a research note on Tuesday, July 28th. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a report on Tuesday, June 2nd. Wall Street Zen upgraded Altimmune from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Finally, Citizens Jmp dropped their price objective on Altimmune from $14.00 to $11.00 and set a “market outperform” rating on the stock in a report on Thursday, May 14th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Arax Advisory Partners raised its position in Altimmune by 99.7% during the fourth quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock worth $29,000 after acquiring an additional 4,076 shares during the period. SBI Securities Co. Ltd. grew its position in shares of Altimmune by 27.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock valued at $32,000 after purchasing an additional 1,928 shares during the period. Quantinno Capital Management LP acquired a new stake in shares of Altimmune in the first quarter valued at about $33,000. Quadrature Capital Ltd acquired a new stake in shares of Altimmune in the fourth quarter valued at about $36,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of Altimmune during the third quarter worth about $38,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Price Performance

NASDAQ:ALT opened at $2.93 on Thursday. The company has a debt-to-equity ratio of 0.12, a current ratio of 29.56 and a quick ratio of 29.56. The company has a 50 day moving average price of $2.90 and a 200-day moving average price of $3.42. Altimmune has a 1-year low of $2.56 and a 1-year high of $6.44. The firm has a market cap of $569.80 million, a price-to-earnings ratio of -3.15 and a beta of 0.27.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 42.57%. Equities research analysts forecast that Altimmune will post -0.64 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.